Focus Sector: Autoimmune Research

MISSION The Flare translates raw clinical trial data into transparent briefings for patients, families, advocacy groups, and independent researchers.

Trauma is not a psychological footnote to autoimmune disease — it is a documented biological risk factor. A 2018 JAMA study tracking 106,464 patients found that those diagnosed with stress-related disorders carried a statistically elevated risk of developing an autoimmune condition compared to matched, unexposed siblings. The mechanism runs deeper than hormone fluctuation. Trauma restructures immune signaling at the epigenetic level, elevates measurable inflammatory markers in the bloodstream, and activates the same pathways that viral infections use to trigger new-onset autoimmune disease. This briefing audits the data behind each of those pathways.

Patients presenting with fatigue, pain, cognitive disruption, and irregular bloodwork are routinely documented as anxious or stressed, often for years, before an autoimmune diagnosis is reached.

This is not anecdotal. A 2020 study published in Rheumatology found that 76% of patients with systemic autoimmune rheumatic diseases reported at least one misdiagnosis before receiving the correct one. Of those misdiagnoses, 47% were mental health or non-organic labels. This is often used to dismiss physical symptoms which contributes to the mean time from first symptom to confirmed diagnosis being nearly seven years. More than 80% of patients said the misdiagnosis still affected them — in some cases decades later.

For lupus, the median diagnostic delay is 47 months. For Sjögren's syndrome, it exceeds 73 months.

The Adverse Childhood Experiences (ACE) score was developed in 1998 through a joint CDC and Kaiser Permanente study of 15,357 adults. It covers ten categories of childhood adversity: physical, emotional, and sexual abuse; witnessing domestic violence; and growing up with household substance abuse, mental illness, parental divorce, or an incarcerated household member.

In clinical research, the ACE score functions as a cumulative stress exposure variable — the same way pack-years of smoking quantifies pulmonary risk. It is not a psychiatric instrument.

The dose-response relationship between ACE score and autoimmune disease is documented (Dube et al., Psychosomatic Medicine, 2009):

A 2025 cohort study published in Psychological Medicine examined over 108,000 women across Iceland and the UK Biobank and found that ACE exposure was associated with higher rates of autoimmune disease across all twelve conditions studied — including Sjögren's, rheumatoid arthritis, and lupus. What the data also showed: depression, anxiety, and PTSD explained only about one quarter of that elevated risk. The other three quarters traced back to biological mechanisms — meaning the body was responding to trauma independently of whether a mental health diagnosis was ever made or recorded.

The effect of trauma on immune function does not resolve when the stressor ends.

Trauma exposure — particularly in early life — can alter the expression of specific stress-response genes through DNA methylation. The primary gene of interest is NR3C1, which encodes the glucocorticoid receptor: the cellular receptor that binds cortisol and governs the body's ability to regulate inflammation. When NR3C1 undergoes trauma-driven methylation changes, cortisol signaling is impaired and the body loses a key brake on immune activation.

These modifications can be long-lasting. A patient whose early stress altered their glucocorticoid receptor gene expression may carry that shifted immune baseline into adulthood — and into every flare and bloodwork panel that follows. Research published in Translational Psychiatry confirmed these NR3C1 methylation patterns are detectable in blood samples, positioning them as a potential future biomarker for trauma-related immune dysregulation.

Viral infections and psychological trauma activate the immune system through overlapping mechanisms — initial innate immune activation, cytokine dysregulation, and aberrations in adaptive immune cell function. The immune system does not distinguish cleanly between a biological invader and a chronic stressor.

A 2023 retrospective cohort study (eClinicalMedicine) examining 1,560,357 individuals found COVID-19 infection associated with a 42.6% higher likelihood of new-onset autoimmune disease within 3 to 15 months of infection. Among those who already had one autoimmune condition, COVID-19 increased the risk of developing a second by 23%.

For patients whose autoimmune symptoms emerged or worsened after a significant viral illness, that exposure belongs in the diagnostic timeline.

Study Name: REVERSE-LC
ClinicalTrials.gov ID: NCT06631287
Lead Sponsor: Vanderbilt University Medical Center
Status: Active — Recruiting | Phase 3
Location: Multiple sites across the continental United States

Who They're Looking For: Adults with confirmed Long COVID experiencing persistent brain fog, cognitive impairment, shortness of breath, or exercise intolerance that has not resolved with standard care.

Mechanism: Baricitinib is a JAK inhibitor already FDA-approved for rheumatoid arthritis. It works by blocking the intracellular signaling pathways that drive pro-inflammatory cytokine production — the same cytokine dysregulation documented in Long COVID and trauma-exposed autoimmune populations. This is the first Long COVID trial to target chronic systemic inflammation as a primary mechanism rather than managing symptoms downstream. Its use here reflects a growing clinical consensus that Long COVID, in a significant subset of patients, is functioning as an immune-dysregulation condition.

C-Reactive Protein (CRP) as a Trauma Exposure Marker

CRP is produced by the liver in response to inflammation and is one of the most routinely ordered markers in standard bloodwork. A widely cited meta-analysis of 20 case-control studies confirmed elevated CRP in PTSD patients compared to controls. A 2017 study of 641 World Trade Center responders found CRP positively associated with PTSD severity — but not with generalized anxiety. That distinction matters: CRP tracked with trauma-specific pathology, not anxiety broadly. For autoimmune patients whose CRP fluctuates without an obvious clinical trigger, a documented trauma history is a variable worth surfacing in the record.

Autoimmune Community Summit — Autoimmune Association
Date: Annual — 2026 dates to be announced
Format: Virtual
Open to: Patients, caregivers, families, and advocates across all autoimmune conditions
Focus: Patient connection, shared experience, research updates, and advocacy. Past summits have covered diagnosis journeys, treatment access, and emerging science across more than 100 autoimmune conditions. Registration and recorded sessions from prior years: autoimmune.org/resource-center/autoimmune-summit

Legal Disclaimer The Flare is an independent investigative journalism outlet. We are not medical providers, clinical trial sites, or financial advisors. This information is for educational and journalistic purposes only and does not constitute medical advice. Always consult a qualified medical professional for health-related decisions. The Flare does not endorse any pharmaceutical product, therapeutic approach, or clinical trial sponsor.